样式: 排序: IF: - GO 导出 标记为已读
-
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2024-03-11 Atsushi Torii, Masahide Oki, Hiroatsu Iida, Arisa Yamada, Yoshihito Kogure, Chiyoe Kitagawa, Hideo Saka
Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD) are rare but well-known diseases that manifest during or after methotrexate (MTX) administration. Limited information is available on the clinical characteristics of OIIA-LPD of the lung because only a few cases have been reported. Thus, we aimed to assess the incidence and prognosis of patients with OIIA-LPD of the
-
Association between pre-ICU aspirin administration and ARDS mortality in the MIMIC-IV database: A cohort study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2024-03-08 Yi Yu, Dengcan Yang, Qianqian Wang, Jian Li
Acute Respiratory Distress Syndrome (ARDS) is a severe condition with high mortality and morbidity rates. Evidence on the effectiveness of pharmacological interventions for ARDS treatment is limited. Recent studies suggest that aspirin may prevent ARDS development, but its efficacy in established ARDS is uncertain. We enrolled patients with ARDS using data from the Medical Information Mart for Intensive
-
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2024-01-17 Ruiming Zhao, Bingbing Xie, Xin Wang, Xinran Zhang, Yanhong Ren, Chen Wang, Huaping Dai
Idiopathic pulmonary fibrosis is a progressive and fatal lung disease lacking effective therapeutics. Treatment with pirfenidone or nintedanib is recommended for patients to delay the progression of their disease. Adverse reactions caused by anti-fibrosis drugs can sometimes interrupt treatment and even change the progression of the disease. This study aimed to investigate the clinical use, adverse
-
Tanshinone IIA alleviates bleomycin-induced pulmonary fibrosis by inhibiting Zbtb16 Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2024-01-06 Huijuan Zhang, Jianli Qiu, Qianyi Zhao, Yong Zhang, Haitao Zheng, Ziying Dou, Yongbin Yan
Pulmonary fibrosis is a complex disease that can occur in a variety of clinical settings. The Zinc Finger and BTB Domain Containing 16 (Zbtb16) is a transcription factor and has not been studied in pulmonary fibrosis. Lung tissues from rats which were treated with bleomycin and Tanshinone IIA (Tan IIA) were collected for mRNA sequencing. Zbtb16, a differentially expressed gene, was screened. Using
-
Epithelial IL5RA promotes epithelial-mesenchymal transition in pulmonary fibrosis via Jak2/STAT3 cascade Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2024-01-06 Shuyun Chen, Tiantian Zhao, Shiguang Xie, Xuan Wan
Pulmonary fibrosis is a progressive and debilitating lung disease characterized by the excessive accumulation of extracellular matrix (ECM) components within the lung parenchyma. However, the underlying mechanism remains largely elusive, and the treatment options available for pulmonary fibrosis are limited. Interleukin 5 receptor, alpha (IL5RA) is a well-established regulator of eosinophil activation
-
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-12-27 Zemin Chen, Haixiong Tang, Sudan Gan, Changyun Yang, Shiyue Li, Jing Li, Lihong Yao
Loss of E-cadherin in the airway epithelial cells is a critical contributor to the development of ALI/ARDS. Yet the underlying mechanisms are largely unknown. Increasing evidences have revealed the significance of ferroptosis in the pathophysiological process of ALI/ARDS. The aim of this study was to investigate the role of ferroptosis in dysregulation of airway epithelial E-cadherin in ALI/ARDS. BALB/c
-
Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-12-22 L. Jayaram, P.T. King, J. Hunt, M. Lim, C. Park, E. Hu, L. Dousha, P. Ha, J.B. Bartlett, A.M. Southcott, S. Muruganandan, S. Vogrin, M.A. Rees, O.M. Dean, C.A. Wong
High dose N acetylcysteine (NAC), a mucolytic, anti-inflammatory and antioxidant agent has been shown to significantly reduce exacerbations, and improve quality of life in placebo controlled, double blind randomised (RCT) studies in patients with COPD, and in an open, randomised study in bronchiectasis. In this pilot, randomised, double-blind, placebo-controlled study, we wished to investigate the
-
The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-12-06 Xiaoxing Wang, Wenwen Du, Dan Zhang, Wenhui Chen, Xianbo Zuo
Lung transplant recipients (LTRs) have a higher risk of hospitalization and mortality due to COVID-19 compared with the immunocompetent population. The use of nirmatrelvir/ritonavir (NR), an effective oral treatment for COVID-19, is quite challenging due to its potent drug-drug interactions with immunosuppressants and azole antifungals. As there are few clinical reports of the use of NR in LTRs, we
-
Can single-inhaler Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium therapy postpone or save biologics for severe asthma? Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-24 Silvano Dragonieri, Vitaliano Nicola Quaranta, Andrea Portacci, Giovanna Elisiana Carpagnano
Inhaled corticosteroids, along with beta2-agonists and anti-muscarinics, represent the cornerstone of asthma treatment. Although the advent of monoclonal antibodies has dramatically changed severe asthma management, there are still patients ineligible or with poor response to biologics. Moreover, high costs associated with monoclonal antibodies prescription are still an open issue, leading clinicians
-
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-28 Tomasz Dębowski, Monika Marko, Barbara Rogala, Paweł Majak, Rafał Pawliczak
Extrafine formulation of beclomethasone/formoterol fixed combination (BDP/F pMDI HFA) is approved for both fixed maintenance and maintenance and reliever therapy (MART) of asthma, and recent data has proven that BDP/F pMDI HFA maintenance and reliever therapy is an effective alternative to other regimens. This study aimed to assess the level of asthma control in a real-life setting in adult patients
-
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-25 Lily Zheng, Mohammad H. Alshaer, Charles Peloquin, Veena Venugopalan, Hassan M. Alnuaimat, Maureen Converse
The impact of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics/dynamics (PK/PD) of beta-lactam antibiotics have not been well studied in general, but cefepime specifically has the least amount of data. We aimed to investigate whether ECMO alters the PK of cefepime in adult intensive care unit (ICU) patients. This single-center, retrospective case-control study evaluated cefepime therapeutic
-
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-15 Audrey Joannes, Tom Voisin, Claudie Morzadec, Alice Letellier, Francisco Llamas Gutierrez, Dan Cristian Chiforeanu, Cécile Le Naoures, Stéphanie Guillot, Bertrand Richard De Latour, Simon Rouze, Madeleine Jaillet, Bruno Crestani, Lutz Wollin, Stéphane Jouneau, Laurent Vernhet
The tyrosine kinase inhibitor nintedanib has been recently approved for the treatment of Interstitial Lung Diseases (ILDs) that manifest a progressive fibrosis phenotype other than Idiopathic pulmonary Fibrosis (IPF). Nintedanib reduces the development of lung fibrosis in various animal models resembling features of PF-ILD and in vitro, it inhibits the fibrosing phenotype of human lung fibroblasts
-
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-13 Akram Tayanloo-Beik, Shayesteh Kokabi Hamidpour, Mohaddese chaharbor, Mostafa Rezaei-Tavirani, Rasta Arjmand, Hossein Adibi, Hamid Ojagh, Bagher Larijani, Babak Arjmand
Chronic obstructive pulmonary disease (COPD) is a respiratory condition characterized by its heterogeneous nature, progressive course, and significant impact on individuals' quality of life. It is a prevalent global health issue affecting a substantial number of individuals and can pose life-threatening complications if left unmanaged. The development and course of COPD can be influenced by a range
-
Tyvaso DPI: Drug-device characteristics and patient clinical considerations Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-13 Colleen McEvoy, Rahul Argula, Sandeep Sahay, Shelley Shapiro, Christina Eagan, Anthony J. Hickey, Chad Smutney, Chris Dillon, Thomas Winkler, Brittany N. Davis, Meredith Broderick, Charles Burger
-
The compound artemisinin-hydroxychloroquine ameliorates bleomycin-induced pulmonary fibrosis in rats by inhibiting TGF-β1/Smad2/3 signaling pathway Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-13 Zhaojia Wang, Min Liu, Ying Ai, Shaoqin Zheng, Yingyi Chen, Hujun Du, Shijia Yuan, Xueying Guo, Yueming Yuan, Guoming Li, Jianping Song, Changsheng Deng
Pulmonary fibrosis (PF) is a lethal disease characterized by a progressive decline in lung function. Currently, lung transplantation remains the only available treatment for PF. However, both artemisinin (ART) and hydroxychloroquine (HCQ) possess potential antifibrotic properties. This study aimed to investigate the effects and mechanisms of a compound known as Artemisinin-Hydroxychloroquine (AH) in
-
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-02 Zhaoyang Li, Mitali Gaurav, Leman Yel
Introduction The recommended standard dose for α1-proteinase inhibitor (A1PI) augmentation therapy is 60 mg/kg once-weekly (QW) intravenous (IV) infusions that aim to maintain systemic A1PI levels >11 μM, the biochemical efficacy threshold, in patients with α1-antitrypsin deficiency (AATD). However, this standard dose may not be optimal for all patients. Body weight–based dosing, alternative dosing
-
IRE1α/XBP-1 promotes β-catenin signaling activation of airway epithelium in lipopolysaccharide-induced acute lung injury Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-11-05 Hailing Zhang, Jiehong Li, Xilong Wang, Kai Wang, JianPeng Xie, Guanjin Chen, Yijian Li, Kai Zhong, Jiahui Li, Xin Chen
Background Acute lung injury (ALI), along with the more severe condition--acute respiratory distress syndrome (ARDS), is a major cause of respiratory failure in critically ill patients with high morbidity and mortality. Inositol-requiring protein 1α (IRE1α)/X box protein-1 (XBP1) pathway was proved to regulate lipopolysaccharide (LPS)-induced lung injury and inflammation. Yet, its role on epithelial
-
Medication use in people with cystic fibrosis before and after modulator therapy Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-10-29 Louise Lord, Mark Hew, Miriam TY. Leung, Jedidiah I. Morton, Jenni Ilomaki
Background Long-term changes in medication dispensings post cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation have not been described. Our study aimed to investigate changes in medication use following the initiation of modulator therapy in people with cystic fibrosis (PwCF) in Australia. Methods Using a 10% sample of the Australian Pharmaceutical Benefits Scheme (PBS)
-
The SIRT3 activator ganoderic acid D regulates airway mucin MUC5AC expression via the NRF2/GPX4 pathway Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-10-23 Jiancheng Wang, Jiayao Li, Yingying He, Xiaochun Huang, Jianguo Feng, Li Liu, Yulin Liu, Xian Jiang, Jing Jia
Purpose The expression of MUC5AC, a highly prevalent airway mucin, is regulated by stimulatory factors such as oxidative stress. Ganoderic acid D (GAD) activates mitochondrial deacetylase SIRT3. SIRT3 regulates mitochondrial function through deacetylation of mitochondrial proteins, thereby playing a significant role in alleviating oxidative stress-related diseases. Therefore, this study aimed to investigate
-
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-09-25 Gabriela Santos, André Fabiano, Patrícia Caetano Mota, Inês Rodrigues, Diogo Carvalho, Natália Melo, Hélder Novais-Bastos, André Terras Alexandre, Conceição Souto Moura, Susana Guimarães, José Miguel Pereira, André Carvalho, António Morais
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that is associated with radiological and/or histological features of usual interstitial pneumonia (UIP). A mean survival of 2–5 years was reported previously to the advent of antifibrotics. According to clinical trials, nintedanib and pirfenidone induce a significant delay in functional decline
-
Nontuberculous mycobacterial (NTM) infections in bronchiectasis patients: A retrospective US registry cohort study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-09-21 Myriam Drysdale, Radmila Choate, Amanda E. Brunton, Simon Tiberi, Iain A. Gillespie, Noah Lininger, Susan B. Shrimpton, Mark Metersky, Nicole C. Lapinel, Pamela J. McShane, Christopher J. Richards, Colin Swenson, Hema Sharma, David Mannino, Kevin L. Winthrop
Rationale Longitudinal epidemiological and clinical data are needed to improve the management of patients with bronchiectasis developing nontuberculous mycobacterial (NTM) pulmonary disease. Objectives To describe the epidemiology, patient management, and treatment outcomes of NTM infections in patients with bronchiectasis enrolled in the United States Bronchiectasis and NTM Research Registry (US BRR)
-
Demethyleneberberine alleviates Pseudomonas aeruginosa-induced acute pneumonia by inhibiting the AIM2 inflammasome and oxidative stress Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-09-17 Yanhong Han, Chuang Ge, Junmei Ye, Ruiyan Li, Yubin Zhang
Background Acute pneumonia induced by Pseudomonas aeruginosa is characterized by massive infiltration of inflammatory cell and the production of reactive oxygen species (ROS), which lead to severe and transient pulmonary inflammation and acute lung injury. However, P.aeruginosa infection is resistant to multiple antibiotics and causes high mortality in clinic, the search for alternative prophylactic
-
Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-09-09 Alaa Ramadan, Mohamed El-Samahy, Amr Elrosasy, Mohammed Al-Tawil, Ahmed Abdelaziz, Mostafa A Soliman, Mohamed Abouzid
Background and objectives Chronic refractory cough is a challenging condition that requires a thorough evaluation and management approach. P2X3 receptors that are ATP-dependent play an important part in nerve fiber sensitization and pathological pain pathways. We conducted this systematic review and meta-analysis to determine the long-term safety and efficacy of P2X3 receptor antagonist drugs in chronic
-
m6A-modified miR-143-3p inhibits epithelial mesenchymal transition in bronchial epithelial cells and extracellular matrix production in lung fibroblasts by targeting Smad3 Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-09-02 Jing Wang, Qiang Jian, Kun Yan, Jiao Yang, Liping Yan, Wei Cheng
-
Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-08-30 Hua Guo, Hui Ren, Kun Han, Jianying Li, Yu Dong, Xuan Zhao, Chunqi Li
HDAC10 has been reported to be associated with poor prognosis in patients with non-small cell lung cancer (NSCLC), however, the regulatory role and mechanisms of HDAC10 in NSCLC have not been investigated. In this study, we found that HDAC10 was increased in NSCLC patients and cell lines. And high expression of HDAC10 is linked to poor survival in NSCLC patients. The results showed that knockdown of
-
Dihydroquercetin (DHQ) ameliorates LPS-induced acute lung injury by regulating macrophage M2 polarization through IRF4/miR-132-3p/FBXW7 axis Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-08-28 Chen Li, Jianhua Liu, Changhong Zhang, Liang Cao, Fang Zou, Zhihua Zhang
Background Acute lung injury (ALI) is a common complication of sepsis. Dihydroquercetin (DHQ) has been found to attenuate lipopolysaccharide (LPS)-induced inflammation. However, the effect of DHQ on LPS-challenged ALI remains unclear. Methods Pulmonary HE and TUNEL staining and lung wet/dry ratio were detected in LPS-treated Balb/c mice. IL-1β, IL-6 and TNF-α levels were determined utilizing ELISA
-
Real world outcomes of CFTR modulator therapy in Australian adults and children Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-08-21 Stephanie Kuek, Angela McCullagh, Eldho Paul, David Armstrong
Background Recent advances in CFTR modulator therapy have the potential to change the face of cystic fibrosis (CF). This retrospective observational study describes real world experience of the four available CFTR modulators in adults and children with CF in a single centre in Melbourne, Australia. Method Data were collected for all patients treated with CFTR modulators at MonashCF between May 2012
-
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-08-20 Magnus Aurivillius, Artur Bednarczyk, Marek Kokot, Jonathan Madriaga, Jie Mei, Kathryn Collison, Raulin Surujbally, James Archbell, Vidya Joshi, Michael Gillen
-
Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-08-09 Angelica Tiotiu, Iulia Ioan, Yves Billon
Background The drug combination elexacaftor-tezacaftor-ivacaftor (ETI) proved highly effective in the improvement of the respiratory symptoms, the percentage of predicted forced expiratory volume in 1 s (FEV1), and to reduce rates of pulmonary exacerbations in people with cystic fibrosis (CF) with at least one F508del mutation. The objectives of the study were to evaluate the impact of ETI on the daily
-
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-08-09 Christina Gress, Jens Vogel-Claussen, Philipp Badorrek, Meike Müller, Kathrin Hohl, Marilisa Konietzke, Tobias Litzenburger, Wolfgang Seibold, Abhya Gupta, Jens M. Hohlfeld
Background Bradykinin 1 receptor (B1R) signalling pathways may be involved in the inflammatory pathophysiology of chronic obstructive pulmonary disease (COPD). B1R signalling is induced by inflammatory stimuli or tissue injury and leads to activation and increased migration of pro-inflammatory cells. Lipopolysaccharide (LPS) lung challenge in man is an experimental method of exploring inflammation
-
SIRT3 alleviates sepsis-induced acute lung injury by inhibiting pyroptosis via regulating the deacetylation of FoxO3a Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-07-25 Zheqian Wu, Yong Wang, Shijie Lu, Lili Yin, Lihua Dai
Objective This study mainly analyzes the mechanism of SIRT3 alleviating sepsis-induced acute lung injury (ALI) by regulating the deacetylation of FoxO3a and inhibiting pyroptosis. Methods SIRT3-overexpressing and silenced BEAS-2B cells were used to evaluate the effect of SIRT3 on apoptosis in LPS-treated lung epithelial cells. FoxO3a-silenced BEAS-2B cells were also used to verify the mechanism by
-
Impact of statin treatment and exposure on the risk of chronic allograft dysfunction in Chinese lung transplant recipients Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-07-16
Purpose Chronic lung allograft dysfunction (CLAD) was a common complication following lung transplantation that contributed to long-term morbidity and mortality. Statin therapy had been suggested to attenuate recipient inflammation and immune response, potentially reducing the risk and severity of CLAD. This study aimed to evaluate the impact of statin use and in vivo exposure on the incidence of CLAD
-
Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-07-13 D. Lachant, R. Minkin, J. Swisher, M. Mogri, R. Zolty, S. Hwang, S. Seaman, M. Broderick, S. Sahay
Purpose Oral treprostinil and selexipag are drugs targeting the prostacyclin pathway and are approved for treatment of pulmonary arterial hypertension (PAH). In the setting of unsatisfactory clinical response or tolerability issues while on selexipag, there is little data on clinical benefit, safety, or strategies on transitioning to oral treprostinil. Using prospective data from the ADAPT registry
-
Safety and usefulness of nebulized liposomal amphotericin B: Systematic scoping review Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-07-04 Hideharu Hagiya, Yoshito Nishimura, Fumio Otsuka
Purpose Invasive fungal infections potentially result in fatal outcomes in immunocompromised hosts. Compared to intravenous administration, a nebulization therapy can achieve a high concentration of drug delivered in the respiratory tract, without a systematic absorption. We herein summarized the study findings on the safety and clinical utility of nebulized liposomal amphotericin B therapy. Methods
-
Assessing the relationship between cardiovascular and small airway disease and acute events in COPD: The ARCADIA study protocol Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-07-04 Paola Rogliani, Dejan Radovanovic, Josuel Ora, Nadia Starc, Stefano Verri, Elena Pistocchini, Luigino Calzetta
The initial alterations of chronic obstructive pulmonary disease (COPD) involve the small airways. Small airway disease (SAD) is related to lung hyperinflation and air trapping. Several lung function tests may detect the presence of SAD, namely forced mid-expiratory flows, residual volume (RV), RV/total lung capacity (TLC) ratio, functional residual capacity, airway resistances obtained with body-plethysmography
-
Amygdalin epimers exert discrepant anti-pulmonary fibrosis activity via inhibiting TGF-β1/Smad2/3 pathway Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-06-25 Haoyan Jiao, Shuyu Li, Qingfa Tang
Idiopathic pulmonary fibrosis (IPF) represents a chronic and progressive tissue repair response that leads to irreversible scarring and lung remodeling. The decoction of bitter almond usually contains amygdalin epimers in traditional clinical application for lung disease. To reveal the differences of cytotoxicity and antifibrotic effect between amygdalin epimers, and potential mechanism is also explored
-
Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-06-22 Jie Wang, Yan-Rong Ma, Ya-e Chang, De-Long Duo, Kun-Kun Duan, Ni Zhao, Wen-Li Cui, Zhi-Lan Huan, Ya-Feng Wang
Hypoxic pulmonary hypertension (HPH) is a devastating disease worldwide; however, effective therapeutic drugs are lacking. This study investigated the effects and underlying mechanisms of LCZ696 treatment on hypoxia-induced pulmonary hypertension. Male Sprague-Dawley (SD) rats were kept in a hypobaric chamber with an oxygen concentration of 5% for 4 weeks. Rats were treated with either LCZ696 (18 mg/kg
-
Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-06-16 Qi Wang, Lin Zhang, Zhenzhong Su, Wei Li, Yuxi Jia, Jie Zhang
This study investigates the molecular mechanism of FTO m6A demethylase in non-small cell lung cancer (NSCLC) and gefitinib resistance using GEO and TCGA databases. Differentially expressed genes (DEGs) were screened from RNA-seq data sets of serum exosomes of gefitinib-resistant NSCLC patients in the GEO database and the NSCLC data set in the GEPIA2 database. From this analysis, FTO m6A demethylase
-
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-06-08 Wenfang Xiong, Shuhua Chen, Hong Xiang, Shaoli Zhao, Jie Xiao, Jialing Li, Yulan Liu, Zhihao Shu, Jie Ouyang, Jing Zhang, Huiqin Liu, Xuewen Wang, Hang Zou, Ying Chen, Alex Chen, Hongwei Lu
Background Idiopathic pulmonary fibrosis (IPF) is a chronic fatal disease of unknown etiology. Its pathological manifestations include excessive proliferation and activation of fibroblasts and deposition of extracellular matrix. Endothelial cell-mesenchymal transformation (EndMT), a novel mechanism that generates fibroblast during IPF, is responsible for fibroblast-like phenotypic changes and activation
-
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-05-23 Valliappan Muthu, Sahajal Dhooria, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Shivaprakash M. Rudramurthy, Ashutosh N. Aggarwal, Arunaloke Chakrabarti, Ritesh Agarwal
Background Allergic bronchopulmonary aspergillosis (ABPA) is complicated by exacerbations in more than one-third of the subjects. Whether nebulized amphotericin B (NAB) therapy prevents ABPA exacerbations remains unclear. Objectives The primary objective of this systematic review and meta-analysis was to determine the frequency of subjects remaining exacerbation-free, one year after initiating NAB
-
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-05-16 Jia Wen Yeap, Irfhan Ali Hyder Ali, Baharudin Ibrahim, Mei Lan Tan
-
Activating transcription factor 6 in the endothelial context Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-04-28 Nektarios Barabutis
Abstract not available
-
Transcriptional factor MAZ promotes cisplatin-induced DNA damage repair in lung adenocarcinoma by regulating NEIL3 Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-04-28 Tao Wang, Xu Zhu, Kai Wang, Jianglun Li, Xiao Hu, Peng Lin, Jian Zhang
Background Cisplatin remains a common chemotherapy drug for lung adenocarcinoma (LUAD) in clinical treatment. Long-term use of cisplatin in patients may lead to acquired drug resistance, resulting in poor prognoses of patients. NEIL3 was a glycosylase-encoding gene highly expressed in LUAD. NEIL3 can repair telomerase DNA damage in the S phase. Nevertheless, there are few reports on whether NEIL3 is
-
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-04-14 Liang Zhao, Zhuo Chen, Jing Cheng, Baojun Chen, Yong Liu
Background Acute lung injury (ALI) may result in severe systemic inflammation and is life-threatening. Remote inflammatory preconditioning (RIPC) has been confirmed to have an endogenous protective effect against ALI. Budesonide (BS) is a potent corticosteroid typically administered through nebulization that reduces inflammation in the lungs. We speculate that the combined use of RIPC and nebulized
-
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-03-27 Gilberto DeNucci, Tom Wilkinson, Carlos Sverdloff, Tainah Babadopulos, Ashley Woodcock, Jan Shute, Pedro Renato Guazelli, Luis Frederico Gerbase, Paulo A.S. Mourão, Dave Singh, Frank M.P. van Haren, Clive Page
There is a strong scientific rationale to use nebulised unfractionated heparin (UFH) in treating patients with COVID-19. This pilot study investigated whether nebulised UFH was safe and had any impact on mortality, length of hospitalisation and clinical progression, in the treatment of hospitalised patients with COVID-19. This parallel group, open label, randomised trial included adult patients with
-
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-03-30 S. Naehrig, B. Schulte-Hubbert, S. Hafkemeyer, J. Hammermann, M. Dumke, S. Sieber, , L. Naehrlich
Background Several clinical guidelines recommend chronic inhaled therapy for pwCF (people with cystic fibrosis) and chronic Pseudomonas aeruginosa infection of the lungs. Methods To demonstrate what kind of therapy regimens are used in Germany, we retrospectively analysed chronic inhaled antibiotic therapy within the cohort of the German CF Registry in 2020. For comparison we also analysed the use
-
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-03-29 Hiromi Tomioka, Masaaki Iwabayashi, Makoto Yokota, Rika Hashimoto, Hisanori Amimoto
Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF). Weight loss is recognized as an adverse event during nintedanib treatment, and is a common complication exploitable as a prognostic indicator of IPF. Here, we report a single-center, retrospective cohort study to assess body weight changes during nintedanib therapy in patients with IPF. Sixty-one patients treated with
-
-
Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-03-11 Chie Kurihara, Reiko Sakurai, Tsai-Der Chuang, Alan J. Waring, Frans J. Walther, Virender K. Rehan
Introduction Hyperoxia-induced lung injury is characterized by acute alveolar injury, disrupted epithelial-mesenchymal signaling, oxidative stress, and surfactant dysfunction, yet currently, there is no effective treatment. Although a combination of aerosolized pioglitazone (PGZ) and a synthetic lung surfactant (B-YL peptide, a surfactant protein B mimic) prevents hyperoxia-induced neonatal rat lung
-
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-03-10 Shanshan Chen, Dandi Gao, Ronghao Sun, Jiali Bao, Chunya Lu, Zihui Zhang, Ting Xiao, Xiaoting Gu, Honggang Zhou
Pulmonary fibrosis is a chronic interstitial fibrosis lung disease with high mortality, which is often complicated with lung cancer. The incidence of IPF complicated with lung cancer is getting higher and higher. At present, there is no consensus on the management and treatment of pulmonary fibrosis patients with lung cancer. There is an urgent need to develop preclinical drug evaluation methods for
-
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-02-24 Malcolm Begg, Augustin Amour, Emily Jarvis, Teresa Tang, Sara Santos Franco, Andrew Want, Misba Beerahee, Disala Fernando, Yakshitha Karkera, Clare Sander, Thomas Southworth, Dave Singh, Jonathan Clark, Sergey Nejentsev, Klaus Okkenhaug, Alison Condliffe, Anita Chandra, Anthony Cahn, Edward Banham Hall
Activated PI3Kδ Syndrome (APDS) is a rare inherited inborn error of immunity caused by mutations that constitutively activate the p110 delta isoform of phosphoinositide 3-kinase (PI3Kδ), resulting in recurring pulmonary infections. Currently no licensed therapies are available. Here we report the results of an open-label trial in which five subjects were treated for 12 weeks with nemiralisib, an inhaled
-
Inhibition of poly (ADP-ribose) Polymerase-1 (PARP-1) improves endothelial function in pulmonary hypertension Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-02-25 Mohammad Shafiq, Zahid Rasool Lone, Adam Olaitan Abdulkareem, Gurpreet Kaur, Sai Navya, Himalaya Singh, Kumaravelu Jagavelu, Kashif Hanif
-
Oncogenic lncRNA MALAT-1 recruits E2F1 to upregulate RAD51 expression and thus promotes cell autophagy and tumor growth in non-small cell lung cancer Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-01-21 Rui Xin, Boqi Hu, Danhua Qu, Dawei Chen
Introduction LncRNA MALAT-1 expression is involved in regulating activities of non-small-cell lung cancer (NSCLC) cells. This study aimed to investigate the effects of lncRNA MALAT-1 on chemosensitivity of NSCLC cells by regulating autophagy. Methods We first validated the expression of lncRNA MALAT-1 in NSCLC cell lines. NSCLC cell lines with high lncRNA MALAT-1 expression were exposed to doxorubicin
-
-
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-01-20 Qiuping Li, Hongying Zhang, Xinpeng Yan, Zhengxiao Zhao, Jian Qiu, Lingli Hu, Shan Jiang, Qing kong, Jing Sun, Lulu Li
Icariin (ICA) might be a potential anti-inflammatory medication in a variety of diseases including COPD, and previous studies showed that ICA could attenuate cigarette smoke (CS)-induced inflammation by inhibiting nuclear factor (NF)-κB. Peroxisome proliferator-activated receptor (PPAR) γ, a nuclear hormone receptor, has been reported to play a critical role in the inflammatory process in COPD. Whether
-
Pulmonary drug delivery for acute respiratory distress syndrome Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-01-20 Qinqin Fei, Ian Bentley, Samir N. Ghadiali, Joshua A. Englert
The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes respiratory failure. Despite numerous clinical trials, there are no molecularly targeted pharmacologic therapies to prevent or treat ARDS. Drug delivery during ARDS is challenging due to the heterogenous nature of lung injury and occlusion of lung units by edema fluid and inflammation. Pulmonary drug delivery
-
Effect of roflumilast on airway remodeling in asthmatic mice exposed to or not exposed to cigarette smoke: Comparison with the effect of dexamethasone Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-01-20 Yukihisa Takeda, Maki Takahashi, Jun-ichi Fuchikami, Hiroyuki Nakamura, Kazutetsu Aoshiba
Cigarette smoking constitutes a risk factor for severe asthma, which is frequently linked to remodeling of the airways. Appropriate drug treatment for smokers with asthma is uncertain because many smokers with asthma are less sensitive to glucocorticoid treatment than non-smokers with asthma. The purpose of this study was to compare the anti-airway remodeling effects of dexamethasone (Dex) and roflumilast
-
Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-01-10 Hyuna Noh, Suhyeon Yoon, Sung-Hee Kim, Jiseon Kim, Jung Seon Seo, Jeong Jin Kim, In Ho Park, Jooyeon Oh, Joon-Yong Bae, Gee Eun Lee, Sun-Je Woo, Sun-Min Seo, Na-Won Kim, Youn Woo Lee, Hui Jeong Jang, Seung-Min Hong, Se-Hee An, Kwang-Soo Lyoo, Minjoo Yeom, Hanbyeul Lee, Je Kyung Seong
-
Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-01-02 Panpan Zhang, Yuanyuan Jia, Zenghui Jing, Jinli Huang, Huajie Wu, Xin Sun
Introduction The aim of this study was to compare the efficacy and safety of 3 years of HDM subcutaneous immunotherapy (HDM-SCIT) in allergic asthma (AA) children with mono- and polysensitized. Methods This was a retrospective observational study, 51 AA children (aged 4–14 years) who had completed 3 years of standardized HDM-SCIT were enrolled in. Based on skin prick tests (SPT) and allergen-specific
-
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score Pulm. Pharmacol. Ther. (IF 3.2) Pub Date : 2023-01-02 Jacob Sellers, Jongwha Chang, Jessica Jones, Trager D. Hintze
Background Remdesivir was the first antiviral to show clinical benefit in patients with moderate-to-severe COVID-19. Previous trials demonstrated a faster time to recovery in hospitalized patients treated with remdesivir vs placebo. Current guidelines recommend treatment with remdesivir based on hospitalization status, oxygen requirements, and time from symptom onset. However, other factors may be